Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ReN 003

Drug Profile

ReN 003

Alternative Names: hRPC therapy - ReNeuron; hRPC-ReNeuron; ReN003; Retinal stem cell therapy-ReNeuron

Latest Information Update: 25 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harvard Medical School; ReNeuron; Schepens Eye Research Institute
  • Developer ReNeuron
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinitis pigmentosa

Most Recent Events

  • 25 Oct 2019 Updated efficacy data from a phase I/IIa trial in Retinitis pigmentosa released by ReNeuron Group
  • 02 Oct 2019 Updated safety and efficacy data from a phase I/IIa trial in Retinitis pigmentosa released by ReNeuron Group
  • 10 Apr 2019 ReN 003 licensed to Shanghai Fosun Pharmaceutical in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top